Challenges in quantifying the patient-reported burden of herpes zoster and post-herpetic neuralgia in the UK: Learnings from the Zoster Quality of Life (ZQOL) study

BMC Research Notes

Volumn 6, Issue 1, 2013, Pages

  Carroll, Stuart ^a   Gater, Adam ^b   Abetz Webb, Linda ^b   Smith, Fiona ^b   Demuth, Dirk ^b   Mannan, Azharul ^a  

^a Sanofi Pasteur MSD   (United Kingdom)

^b ADELPHI REAL WORLD   (United Kingdom)

Author keywords

Burden; Herpes zoster; Post herpetic neuralgia; Real world

Indexed keywords

HERPES ZOSTER;

AGED; ARTICLE; COST OF ILLNESS; ECONOMICS; ETHICS; FEMALE; HERPES ZOSTER; HUMAN; INFORMATION PROCESSING; MALE; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PATIENT SATISFACTION; PATIENT SELECTION; POSTHERPETIC NEURALGIA; PRIMARY HEALTH CARE; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; UNITED KINGDOM;

AGED; COST OF ILLNESS; DATA COLLECTION; FEMALE; GREAT BRITAIN; HERPES ZOSTER; HUMANS; MALE; MIDDLE AGED; NEURALGIA, POSTHERPETIC; PATIENT SATISFACTION; PATIENT SELECTION; PRIMARY HEALTH CARE; QUALITY OF LIFE; RESEARCH DESIGN;

EID: 84888102701     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-6-486     Document Type: Article

References (50)

1. Cohen J, Powderly WG, Berkley SF, Calandra T, Clumeck N, Finch RG, Infectious diseases. 2nd ed London: Mosby 2003
2. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Brisson M, Edmunds WJ, Law B, Gay NJ, Walld R, Brownell M, Roos L, De SG, Epidemiol Infect 2001 127 2 305 314 11693508 (Pubitemid 33019542)
3. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Edmunds WJ, Brisson M, Rose JD, Vaccine 2001 19 23-24 3076 3090 11312002 (Pubitemid 32324035)
4. The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. Schmader K, Gnann JW, Watson CP, J Infect Dis 2008 197 Supplement 2 207 S215 18419399
5. Dworkin RH, Schmader KE, The epidemiology and natural history of herpes zoster and postherpetic neuralgia Amsterdam: Elsevier Herpes zoster and postherpetic neuralgia. 2nd ed. 2001 39 64
6. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. Drolet M, Brisson M, Schmader KE, Levin MJ, Johnson R, Oxman MN, Patrick D, Blanchette C, Mansi JA, Can Med Assoc J 2010 182 16 1731 1736 10.1503/cmaj.091711
7. The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Schmader KE, Sloane R, Pieper C, Coplan PM, Nikas A, Saddier P, Chan IS, Choo P, Levin MJ, Johnson G, Williams HM, Oxman MN, Clin J Pain 2007 23 6 490 496 10.1097/AJP.0b013e318065b6c9 17575488 (Pubitemid 46956185)
8. A cross-sectional survey of health state impairment and treatment patterns in patients with postherpetic neuralgia. van Seventer R, Sadosky A, Lucero M, Dukes E, Age Ageing 2006 35 2 132 137 10.1093/ageing/afj048 16431855
9. The burden of Herpes Zoster: a prospective population based study. Scott FT, Johnson RW, Leedham-Green M, Davies E, Edmunds WJ, Breuer J, Vaccine 2006 24 9 1308 1314 10.1016/j.vaccine.2005.09.026 16352376 (Pubitemid 43222038)
10. Pain, medication Use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. Oster G, Harding G, Dukes E, Edelsberg J, Cleary PD, J Pain 6 6 356 363 6-1-2005. http://linkinghub.elsevier.com/retrieve/pii/S1526590005004153?showall=true
11. Acute pain in herpes zoster and its impact on health-related quality of life. Katz J, Cooper EM, Walther RR, Sweeney EW, Dworkin RH, Clin Infect Dis 2004 39 3 342 348 10.1086/421942 15307000 (Pubitemid 39050481)
12. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. Johnson RW, Bouhassira D, Kassianos G, Leplege A, Schmader KE, Weinke T, BMC Med 2010 8 37 10.1186/1741-7015-8-37 20565946
13. Characteristics of patients with herpes zoster on presentation to practitioners in France. Chidiac C, Bruxelle J, Daures JP, Hoang-Xuan T, Morel P, Leplege A, El Hasnaoui A, De Labareyre C, Pain Pract 2001 1 4 381
14. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Gauthier A, Breuer J, Carrington D, Martin M, Remy V, Epidemiol Infect 2009 137 1 38 47 10.1017/S0950268808000678 18466661
15. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Rothberg MB, Virapongse A, Smith KJ, Clin Infect Dis 2007 44 10 1280 1288 10.1086/514342 17443464 (Pubitemid 46717289)
16. Healthcare costs of acute and chronic pain associated with a diagnosis of herpes zoster. Dworkin RH, White R, O'Connor AB, Baser O, Hawkins K, J Am Geriatr Soc 2007 55 8 1168 1175 10.1111/j.1532-5415.2007.01231.x 17661954 (Pubitemid 47106670)
17. Health care utilization and cost burden of herpes zoster in a community population. Yawn BP, Itzler RF, Wollan PC, Pellissier JM, Sy LS, Saddier P, Mayo Clin Proc 2009 84 9 787 794 10.4065/84.9.787 19720776
18. Acute/subacute herpes zoster: healthcare resource utilisation and costs in a group of US health plans. Insinga RP, Itzler RF, Pellissier JM, Pharmacoeconomics 2007 25 2 155 169 10.2165/00019053-200725020-00007 17249857 (Pubitemid 46175551)
19. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia. Brisson M, Pellissier JM, Camden S, Quach C, De WP, Hum Vaccin 2008 4 3 238 245 10.4161/hv.4.3.5686 18382137
20. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, Weinberg A, Boardman KD, Williams HM, Zhang JH, Peduzzi PN, Beisel CE, Morrison VA, Guatelli JC, Brooks PA, Kauffman CA, Pachucki CT, Neuzil KM, Betts RF, Wright PF, Griffin MR, Brunell P, Soto NE, Marques AR, Keay SK, Goodman RP, Cotton DJ, Gnann JW Jr, Loutit J, Holodniy M, Keitel WA, Crawford GE, Yeh SS, Lobo Z, Toney JF, Greenberg RN, Keller PM, Harbecke R, Hayward AR, Irwin MR, Kyriakides TC, Chan CY, Chan IS, Wang WW, Annunziato PW, Silber JL, N Engl J Med 2005 352 22 2271 2284 10.1056/NEJMoa051016 15930418 (Pubitemid 40740551)
21. Department of Health, Equity and excellence: liberating the NHS (White Paper) London: TSO 2010
22. A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK. Moore L, Remy V, Martin M, Beillat M, McGuire A, Cost Eff Resour Alloc 2010 8 7 10.1186/1478-7547-8-7 20433704
23. Joint Committee on Vaccination and Immunisation, Minutes of the meeting held on 14 october 2009 London 2009
24. Joint Committee on Vaccination and Immunisation Varicellar Subgroup, Minutes of the varicella JCVI subgroup meeting on Monday 9th March London 2009
25. Primary care management of acute herpes zoster: systematic review of evidence from randomized controlled trials. Lancaster T, Silagy C, Gray S, Br J Gen Pract 1995 45 390 39 45 7779475
26. Herpes zoster and postherpetic neuralgia: prevention and management. Mounsey AL, Matthew LG, Slawson DC, Am Fam Physician 2005 72 6 1075 1080 16190505 (Pubitemid 43093262)
27. Treatment of herpes zoster. Opstelten W, Eekhof J, Neven AK, Verheij T, Can Fam Physician 2008 54 3 373 377 18337531 (Pubitemid 351413661)
28. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. Coplan PM, Schmader K, Nikas A, Chan IS, Choo P, Levin MJ, Johnson G, Bauer M, Williams HM, Kaplan KM, Guess HA, Oxman MN, J Pain 2004 5 6 344 356 10.1016/j.jpain.2004.06.001 15336639 (Pubitemid 39164674)
29. The MOS 36-item short-form health survey (SF-36) I. Conceptual framework and item selection. Ware JE Jr, Sherbourne CD, Med Care 1992 30 6 473 483 10.1097/00005650-199206000-00002 1593914
30. EQ-5D: a measure of health status from the EuroQol Group. Rabin R, De CF, Ann Med 2001 33 5 337 343 10.3109/07853890109002087 11491192 (Pubitemid 32675374)
31. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, Rowland CR, Health Qual Life Outcomes 2004 2 12 12 14987333
32. Herpes zoster and quality of life: a self-limited disease with severe impact. Lydick E, Epstein RS, Himmelberger D, White CJ, Neurology 1995 45 12 Suppl 8 52 S53 8545021
33. Clinical and psychosocial correlates of acute pain in herpes zoster. Volpi A, Gatti A, Serafini G, Costa B, Suligoi B, Pica F, Marsella LT, Sabato E, Sabato AF, J Clin Virol 2007 38 4 275 279 10.1016/j.jcv.2007.01.010 17339131 (Pubitemid 46414008)
34. SF-36 v2 US population norms 1998 http://www.sf-36.org/research/ sf98norms.pdf
35. Kind P, Hardman G, Macran S, UK population norms for EQ-5D Centre for Health Economics, University of York 1999 http://econpapers.repec.org/paper/ chyrespap/172chedp.htm
36. Short report: how often do UK primary care trials face recruitment delays? Bower P, Wilson S, Mathers N, Fam Pract 2007 24 6 601 603 10.1093/fampra/cmm051 17872907
37. 'Will you help me with my research?' gaining access to primary care settings and subjects. Murphy E, Spiegal N, Kinmonth AL, Br J Gen Pract 1992 42 357 162 165 1586554
38. Simply no time? Barriers to GPs' participation in primary health care research. Hummers-Pradier E, Scheidt-Nave C, Martin H, Heinemann S, Kochen MM, Himmel W, Fam Pract 2008 25 2 105 112 10.1093/fampra/cmn015 18417465 (Pubitemid 351753541)
39. Department of Health, Governance arrangements for research ethics committees, a harmonized edition London 2011
40. Obstacles to conducting epidemiological research in the UK general population. Ward HJ, Cousens SN, Smith-Bathgate B, Leitch M, Everington D, Will RG, Smith PG, BMJ 2004 329 7460 277 279 10.1136/bmj.329.7460.277 15284154 (Pubitemid 39061338)
41. The other face of research governance. Jones AM, Bamford B, BMJ 2004 329 7460 280 281 10.1136/bmj.329.7460.280 15284155 (Pubitemid 39061339)
42. Bureaucracy of ethics applications. Wald DS, BMJ 2004 329 7460 282 284 10.1136/bmj.329.7460.282 15284157 (Pubitemid 39061341)
43. Research ethics committees in the UK-the pressure is now on research and development departments. Al-Shahi R, J R Soc Med 2005 98 10 444 447 10.1258/jrsm.98.10.444 16199810 (Pubitemid 41497538)
44. Multicentre research ethics committees: has the cure been worse than the disease? No, but idiosyncracies and obstructions to good research must be removed. Alberti KG, BMJ 2000 320 7243 1157 1158 10.1136/bmj.320.7243.1157 10784526 (Pubitemid 30224260)
45. Research ethics paperwork: what is the plot we seem to have lost? Jamrozik K, BMJ 2004 329 7460 286 287 10.1136/bmj.329.7460.286 15284159 (Pubitemid 39061343)
46. Cohen J, Statistical power analysis for the behaviora sciences Hillsdale, NJ: Erlbaum 2 1988
47. What influences recruitment to randomised controlled trials? A review of trials funded by two UK funding agencies. McDonald AM, Knight RC, Campbell MK, Entwistle VA, Grant AM, Cook JA, Elbourne DR, Francis D, Garcia J, Roberts I, Snowdon C, Trials 2006 7 9 10.1186/1745-6215-7-9 16603070 (Pubitemid 43862982)
48. Falling research in the NHS. Rees M, Wells F, BMJ 2010 340 2375 10.1136/bmj.c2375 20478962
49. ABPI, The vision for real world data-harnessing the opportunities in the UK London: White Paper 2011
50. Department of Health, A new value-based approach to the pricing of branded medicines-a consultation (Available at http://webarchive. nationalarchives.gov.uk/ +/ www.dh.gov.uk/en/consultations/liveconsultations/dh- 122760). 2010